← Human Trials & Peer-Reviewed Studies
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis
Plain-language guide to PMID 17164314 (2007): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 178 women.
Key Facts
- PMID
- 17164314
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Antoniucci DM et al. (7 authors)
- DOI
- 10.1210/jc.2006-1788
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.
The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated.
Who Took Part
According to the abstract, 178 women were involved.
The age groups tagged for this paper are middle-aged adults and older adults, women only.
A total of 178 postmenopausal women were randomized to PTH(1-84) either alone or in combination with alendronate during the first year of the PaTH study.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.
As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.
What Was Measured
The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated.
PubMed files the paper under topics including Alendronate, Algorithms, Bone Density Conservation Agents, Calcium, Hypercalcemia, Hypercalciuria and Osteoporosis, Postmenopausal.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 178 women.
The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.